NanoEcho AB
SSTO:NANECH0.01
SEK
-0.01
(-37.50%)
ISIN
SE0017133705
Return %
Stock
S&P 500
1Y
-85.47
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Björn Oskar Larsson
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lund Sweden
- IPO Date
- Aug 6, 2024
- Website
- nanoecho.se
- Similar Companies
- Business
- NanoEcho AB is a clinical-stage medical technology company that develops non-invasive diagnostic imaging solutions for oncology, with a primary focus on the pre-operative staging and lymph node assessment of rectal cancer. The company utilizes a patented magnetomotive ultrasound platform combining targeted nanotechnology and ultrasound imaging to detect cancer dissemination prior to surgery. Its core product and service offerings comprise proprietary magnetomotive ultrasound imaging systems designed for transrectal diagnostic examinations; biocompatible iron oxide nanoparticle contrast agents formulated for targeted uptake in regional lymph nodes; integrated diagnostic hardware including external magnetic field induction units and specialized ultrasound probes; proprietary image reconstruction and signal processing software that captures and visualizes nanoparticle movement within tissues; and technical consulting, system maintenance, and clinical research support services for medical institutions. The company operates within the healthcare equipment and diagnostic oncology sectors, targeting university hospitals, specialized cancer centers, colorectal surgery units, and clinical research organizations initially across Sweden and Europe, with long-term expansion plans into global markets. Founded in 2013 as an academic spin-off from Lund University, NanoEcho AB is headquartered in Lund, Sweden, and is publicly listed on the Nasdaq First North Growth Market under the ticker symbol NANECH. In recent developments, NanoEcho AB has achieved significant clinical, commercial, and organizational milestones. In 2026, the company recorded its first commercial revenue from diagnostic system sales, closed a bridge financing facility with existing shareholders, and executed a rights issue to fund clinical validation programs and regulatory preparations. Clinically, NanoEcho advanced patient investigations following approval from the Swedish Medical Products Agency, successfully reporting preliminary clinical results from its Proof of Concept evaluation study alongside published health-economic analyses validating the system's cost efficiency in standard cancer care pathways. On the governance and executive level, the company restructured its leadership in 2026 by appointing Nils Löfgren as Chief Financial Officer and transitioning Björn Larsson to acting Chief Executive Officer, while steering the diagnostic system toward European regulatory clearance and market authorization.